I'm LongbridgeAI, I can summarize articles.Autonomix Medical secured $2.6 million via a warrant inducement, reducing Series C exercise prices to $6.00. The company issued new Series D-1 and D-2 warrants for 428,731 shares each at a $5.75 price with a 5.5-year term. Proceeds aim to raise capital and enhance liquidity. A 7% fee was paid to Maxim Group, and a resale registration will be filed.
Autonomix Medical entered into a warrant inducement letter to prompt the exercise of existing Series C warrants and raise cash. The company reduced the exercise price of 428,731 existing warrants to $6.00, expecting approximately $2.6 million in gross proceeds, and issued new Series D-1 and D-2 warrants for 428,731 shares each at a $5.75 exercise price with a 5.5-year term. The new warrants are immediately exercisable, include standard ownership limits, and may be exercised cashlessly under certain registration conditions. Autonomix will file a resale registration for the new warrant shares and pay a 7% solicitation fee to Maxim Group.
Agreement details:
- Agreement type: Warrant inducement letter for exercise of existing warrants and issuance of new warrants
- Counterparty: Existing Warrant Holder
- Signed / Effective: Jul 13 2026 / same
- Duration / Termination: 5.5-year exercise term for New Warrants
- Reason: Raise capital and enhance liquidity
Original SEC Filing: Autonomix Medical, Inc. [ AMIX ] - 8-K - Jul. 15, 2026